Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) EV-to-EBIT : -1.45 (As of May. 12, 2024)

Brainstorm Cell Therapeutics EV-to-EBIT Chart

Brainstorm Cell Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBIT		Get a 7-Day Free Trial					-4.39	-3.93	-5.24	-2.47	-0.77

Brainstorm Cell Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-2.47	-5.24	-3.88	-0.49	-0.77

Competitive Comparison of Brainstorm Cell Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brainstorm Cell Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's EV-to-EBIT falls into.

Brainstorm Cell Therapeutics EV-to-EBIT Calculation

Brainstorm Cell Therapeutics's EV-to-EBIT for today is calculated as:

Brainstorm Cell Therapeutics's current Enterprise Value is $31.14 Mil.
Brainstorm Cell Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brainstorm Cell Therapeutics  (NAS:BCLI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Brainstorm Cell Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Brainstorm Cell Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $16.49 Mil.
Brainstorm Cell Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brainstorm Cell Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Business Description